Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2014; 20(9): 2279-2303
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2279
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2279
Table 4 Most common genetic alterations observed in different types of human pancreatic cancers
| Type of pancreatic cancer | Gene affected | Ref. |
| Pancreatic ductal adenocarcinoma (PDAC) | KRAS, AKT, MYC, TP53, SMAD4, CDKN2A, PTEN | [55,63,64,73,78,79,94,269,284-287] |
| (90% of all pancreatic cancers) | ||
| Acinar cell carcinoma (ACCA) | APC/β-catenin (CTNNB1), BRCA2, BCL10 | [288-290] |
| (< 1% of all pancreatic cancers) | ||
| Adenosquamous carcinoma (ASC) | TP53, CDKN2A, KRAS, E-cadherin, | [291,292] |
| (< 1% of all pancreatic cancers) | ||
| Intraductal papillary mucinous neoplasm (IPNM) | GNAS, KRAS, RNF4, STK11/LKB1, MUC1, MUC2, hTERT, COX2, Shh | [278,293,294] |
| (1%-3% of all pancreatic cancers) | ||
| Mucinous cystic neoplasm (MCN) | KRAS, RNF4, TP53, CDKN2A | [295] |
| (< 1% of all pancreatic cancers) | ||
| Serous cystadenoma (SCN) | VHL | [296] |
| (< 1% of all pancreatic cancers) | ||
| Solid-pseudopapillary neoplasm (SPN) | APC/β-catenin (CTNNB1), E-cadherin | [297,298] |
| (1%-2% of all pancreatic cancers) | ||
| Pancreatic neuroendocrine tumors (PanNET) | DAXX, ATRX, MEN1, TSC2, PTEN, PI3KCA, CHGA, CHGB, mTOR | [299-302] |
| (2%-5% of all pancreatic cancers) |
- Citation: Swierczynski J, Hebanowska A, Sledzinski T. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol 2014; 20(9): 2279-2303
- URL: https://www.wjgnet.com/1007-9327/full/v20/i9/2279.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i9.2279